Entera Bio Ltd. EV/Sales

EV/Sales of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/Sales growth rates and interactive chart. Compares the total enterprise value of a company to its sales. It is a more accurate measure of business value, as it takes into account cash and debt on the balance sheet. A company with large cash holdings and no debt will show a significantly lower EV/S than P/S ratio.

Highlights and Quick Summary

Current EV/Sales of Entera Bio Ltd. is 14.85 (as of December 30, 2019)
  • EV/Sales for the quarter ending June 29, 2020 was 93.22 (a 8.22% increase compared to previous quarter)
  • Year-over-year quarterly EV/Sales increased by Infinity%
  • Annual EV/Sales for 2019 was 14.85 (a Infinity% increase from previous year)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/Sales of Entera Bio Ltd.

Most recent EV/Salesof ENTX including historical data for past 10 years.

Interactive Chart of EV/Sales of Entera Bio Ltd.

Entera Bio Ltd. EV/Sales for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 93.22 86.14
2019 14.85 0.0 0.0 14.85
2018 0.0 0.0

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.